Amy Wendell has served as a member of the board of directors of AxoGen, Inc. since September 2016 and was appointed Lead Director in May 2018. From 1986 until January 2015, Ms. Wendell held various roles of increasing responsibility at Covidien plc (including its predecessors, Tyco Healthcare and Kendall Healthcare Products), including engineering, product management and business development. Most recently, from December 2006 until Covidien's acquisition by Medtronic plc in January 2015, she served as Senior Vice President of Strategy and Business Development, where she led the company's strategy and portfolio management initiatives and managed all business development, including acquisitions, equity investments, divestitures and licensing/distribution. Since 2015, Ms. Wendell has been a Senior Advisor for McKinsey's Strategy and Corporate Finance Practice as well as a member of McKinsey's Transactions Advisory Board to help define trends in Mergers & Acquisitions, as well as help shape McKinsey's knowledge agenda. Since January 2016, Ms. Wendell has also been a Senior Advisor for Perella Weinberg Partner's Healthcare Investment Banking Practice. Her scope of responsibilities involves providing guidance and advice with respect to Mergers & Acquisitions and divestures for clients and assisting the firm with activities related to firm-level transactions. Ms. Wendell Is a member of the board of directors of Hologics. She is also a director of Por Cristo, a non-profit charitable medical service organization involved in health care work for at-risk women and children in Latin America. Ms. Wendell holds a Bachelor of Science degree in Mechanical Engineering from Lawrence Technological University and a Master of Science degree in Biomedical Engineering from the University of Illinois.